2 results
Approved WMOCompleted
To assess uptake of 18F-PD-L1 and 89Zr- nivolumab in tumor lesions.
Approved WMOCompleted
The primary objective of the main non-inferiority study is to determine the safety of TACmono starting nine months after kidney transplantation in immunologically low-risk patients in terms of BPAR-rate 15 months after transplantation compared to…